| pubmed-article:7815631 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7815631 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:7815631 | lifeskim:mentions | umls-concept:C0021758 | lld:lifeskim |
| pubmed-article:7815631 | lifeskim:mentions | umls-concept:C0022665 | lld:lifeskim |
| pubmed-article:7815631 | lifeskim:mentions | umls-concept:C0027627 | lld:lifeskim |
| pubmed-article:7815631 | lifeskim:mentions | umls-concept:C0677930 | lld:lifeskim |
| pubmed-article:7815631 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:7815631 | lifeskim:mentions | umls-concept:C0443211 | lld:lifeskim |
| pubmed-article:7815631 | lifeskim:mentions | umls-concept:C0392752 | lld:lifeskim |
| pubmed-article:7815631 | lifeskim:mentions | umls-concept:C1512954 | lld:lifeskim |
| pubmed-article:7815631 | lifeskim:mentions | umls-concept:C0205225 | lld:lifeskim |
| pubmed-article:7815631 | lifeskim:mentions | umls-concept:C0591833 | lld:lifeskim |
| pubmed-article:7815631 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:7815631 | pubmed:dateCreated | 1995-2-6 | lld:pubmed |
| pubmed-article:7815631 | pubmed:abstractText | In an effort to develop new strategies for immunotherapy of metastatic renal cell carcinoma, we investigated the therapeutic potential of interleukin-4 in a visceral renal tumor using the murine Renca renal adenocarcinoma model. Renca cells were implanted underneath the renal capsule of Balb/c mice to induce a primary tumor that spontaneously metastasized to several organs. Established primary renal tumors 4 to 6 mm. in diameter were treated by intralesional administration of recombinant murine interleukin-4 (IL-4). This treatment caused a marked inhibition of the primary tumor growth but had little effect on the progression of metastases in the liver, mesentery and lungs. Immunohistochemistry studies performed on renal tumor sections showed a macrophage infiltration that became predominant 7 days after IL-4 treatment. CD8+ T cells were also observed at the periphery and within the tumor. These data suggest that IL-4 mediated a potent antitumor effect when administered intralesionally although its effects remained localized with no impact on metastases at distant sites. Interleukin-4 antitumor activity seems to be mediated by recruitment of macrophages and T cells in the tumor. | lld:pubmed |
| pubmed-article:7815631 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7815631 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7815631 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7815631 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:7815631 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7815631 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7815631 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7815631 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:7815631 | pubmed:issn | 0022-5347 | lld:pubmed |
| pubmed-article:7815631 | pubmed:author | pubmed-author:PontesJ EJE | lld:pubmed |
| pubmed-article:7815631 | pubmed:author | pubmed-author:PuriR KRK | lld:pubmed |
| pubmed-article:7815631 | pubmed:author | pubmed-author:HaasG PGP | lld:pubmed |
| pubmed-article:7815631 | pubmed:author | pubmed-author:HillmanG GGG | lld:pubmed |
| pubmed-article:7815631 | pubmed:author | pubmed-author:YounesEE | lld:pubmed |
| pubmed-article:7815631 | pubmed:author | pubmed-author:VisscherDD | lld:pubmed |
| pubmed-article:7815631 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7815631 | pubmed:volume | 153 | lld:pubmed |
| pubmed-article:7815631 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7815631 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7815631 | pubmed:pagination | 490-3 | lld:pubmed |
| pubmed-article:7815631 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:7815631 | pubmed:meshHeading | pubmed-meshheading:7815631-... | lld:pubmed |
| pubmed-article:7815631 | pubmed:meshHeading | pubmed-meshheading:7815631-... | lld:pubmed |
| pubmed-article:7815631 | pubmed:meshHeading | pubmed-meshheading:7815631-... | lld:pubmed |
| pubmed-article:7815631 | pubmed:meshHeading | pubmed-meshheading:7815631-... | lld:pubmed |
| pubmed-article:7815631 | pubmed:meshHeading | pubmed-meshheading:7815631-... | lld:pubmed |
| pubmed-article:7815631 | pubmed:meshHeading | pubmed-meshheading:7815631-... | lld:pubmed |
| pubmed-article:7815631 | pubmed:meshHeading | pubmed-meshheading:7815631-... | lld:pubmed |
| pubmed-article:7815631 | pubmed:meshHeading | pubmed-meshheading:7815631-... | lld:pubmed |
| pubmed-article:7815631 | pubmed:meshHeading | pubmed-meshheading:7815631-... | lld:pubmed |
| pubmed-article:7815631 | pubmed:meshHeading | pubmed-meshheading:7815631-... | lld:pubmed |
| pubmed-article:7815631 | pubmed:meshHeading | pubmed-meshheading:7815631-... | lld:pubmed |
| pubmed-article:7815631 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7815631 | pubmed:articleTitle | Intralesional treatment of established murine primary renal tumor with interleukin-4: localized effect on primary tumor with no impact on metastases. | lld:pubmed |
| pubmed-article:7815631 | pubmed:affiliation | Department of Urology, Wayne State University School of Medicine, Detroit, Michigan 48201. | lld:pubmed |
| pubmed-article:7815631 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7815631 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7815631 | lld:pubmed |
